

DAFTAR PUSTAKA

- Abul Abbas, Andrew Lichtman, S. P. (2019) *Cellular and Molecular Immunology*.
- Adhoute, X. *et al.* (2016) '2016 Hepatocellular Carcinoma : Global view Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments', 8(17), pp. 703–715. doi: 10.4254/wjh.v8.i17.703.
- Aino, H. *et al.* (2016) 'The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis', pp. 83–88. doi: 10.3892/mco.2016.879.
- Arvanitakis, K., Mitroulis, I. and Germanidis, G. (2021) 'Tumor-Associated Neutrophils in Hepatocellular Carcinoma', pp. 1–17.
- Balmasova, I. P. *et al.* (2014) 'Immunopathogenesis of chronic hepatitis B', 20(39), pp. 14156–14171. doi: 10.3748/wjg.v20.i39.14156.
- Bosetti, C., Turati, F. and La Vecchia, C. (2014) 'Hepatocellular carcinoma epidemiology', *Best Practice and Research: Clinical Gastroenterology*, 28(5), pp. 753–770. doi: 10.1016/j.bpg.2014.08.007.
- Caines, A. (2022) 'The Changing Global Epidemiology of Hepatocellular Carcinoma', *Clinics in Liver Disease*, 24(4), pp. 535–547. doi: 10.1016/j.cld.2020.06.001.
- Chang, M. *et al.* (2000) 'Hepatitis B Vaccination and Hepatocellular Carcinoma Rates in Boys and Girls', 284(23), pp. 18–20.
- Chinen, J. and Shearer, W. T. (2002) 'Molecular virology and immunology of HIV infection', *Journal of Allergy and Clinical Immunology*, 110(2), pp. 189–198. doi: 10.1067/mai.2002.126226.
- Choo, S. P. *et al.* (2016) 'Comparison of hepatocellular carcinoma in Eastern versus Western populations', *Cancer*, 122(22), pp. 3430–3446. doi: 10.1002/cncr.30237.

- Dahlan, M. S. (2013) *Besar Sampel dan Cara Pengambilan Sampel*. Tiga. Jakarta: Salemba Medika.
- Darmadi, D., Ruslie, R. H. and Pakpahan, C. (2021) ‘Vascular Endothelial Growth Factor Levels Difference among Hepatocellular Cancer Patients Based on Barcelona Clinic Liver Cancer Staging’, 9, pp. 797–800.
- Dhanasekaran, R., Bandoh, S. and Roberts, L. R. (2016) ‘Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances [version 1 ; referees : 4 approved] Referee Status ’, 5(May), pp. 1–15.
doi: 10.12688/f1000research.6946.1.
- Goh, G. B. B., Chang, P. E. and Tan, C. K. (2015) ‘Changing epidemiology of hepatocellular carcinoma in Asia’, *Best Practice and Research: Clinical Gastroenterology*, 29(6), pp. 919–928. doi: 10.1016/j.bpg.2015.09.007.
- Goossens, N. and Hoshida, Y. (2015) ‘Hepatitis C virus-induced hepatocellular carcinoma’, pp. 105–114.
- Gumilas, N. S. A. *et al.* (2019) ‘Hepatitis B as hepatocellular carcinoma (HCC) risk factor in the south region of Java, Indonesia’, *Journal of Physics: Conference Series*, 1246(1). doi: 10.1088/1742-6596/1246/1/012013.
- Hsu, C. Y. *et al.* (2010) ‘Selecting an optimal staging system for hepatocellular carcinoma: Comparison of 5 currently used prognostic models’, *Cancer*, 116(12), pp. 3006–3014. doi: 10.1002/cncr.25044.
- Hu, B. *et al.* (2014) ‘Systemic Immune-In fl ammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma’, 20(16), pp. 6212–6222. doi: 10.1158/1078-0432.CCR-14-0442.
- Iadecola, C. and Anrather, J. (2011) ‘The immunology of stroke: From mechanisms to translation’, *Nature Medicine*, 17(7), pp. 796–808. doi: 10.1038/nm.2399.
- Kanwal, F. *et al.* (2019) ‘Long-Term Risk of Hepatocellular Direct Acting Antiviral Agents’, 0(0), pp. 1–12. doi: 10.1002/hep.30823.

- Kasper. Dennis (2015), *Harrison's Principles of Internal 19 th edition*, Mc Graw Hill Education Publisher, pp. 544-533.
- Kemenkes RI (2018) 'Hasil Riset Kesehatan Dasar Tahun 2018', *Kementrian Kesehatan RI*, 53(9), pp. 1689–1699.
- Kinoshita, A. *et al.* (2012) 'Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma', *British Journal of Cancer*, pp. 988–993. doi: 10.1038/bjc.2012.354.
- Kristina, S. A. (2021) 'The medical cost of liver cancer in a referral hospital in Indonesia during 2020', 11(12), pp. 135–138.
doi: 10.7324/JAPS.2021.1101212.
- Kudo, M. *et al.* (2020) 'A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements', *Liver Cancer*, 9(3), pp. 245–260.
doi: 10.1159/000507370.
- Kulik, L. and El-serag, H. B. (2022) 'Epidemiology and Management of Hepatocellular Carcinoma', *Gastroenterology*, 156(2), pp. 477-491.e1.
doi: 10.1053/j.gastro.2018.08.065.
- Kulik, L. and El-Serag, H. B. (2019) 'Epidemiology and Management of Hepatocellular Carcinoma', *Gastroenterology*, 156(2), pp. 477-491.e1.
doi: 10.1053/j.gastro.2018.08.065.
- Laurent-Puig, P. and Zucman-Rossi, J. (2006) 'Genetics of hepatocellular tumors', *Oncogene*, 25(27), pp. 3778–3786. doi: 10.1038/sj.onc.1209547.
- Laurentius. Lesmana (2017) 'Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati', 2017.
- Leong, T. Y. M. and Leong, A. S. Y. (2005) 'Epidemiology and carcinogenesis of hepatocellular carcinoma', *Hpb*, 7(1), pp. 5–15.
doi: 10.1080/13651820410024021.

- Lu, L., Hsu, C. and Cheng, A. (2016) 'Tumor Heterogeneity in Hepatocellular Carcinoma : Facing the Challenges', pp. 128–138. doi: 10.1159/000367754.
- Lv, Y. *et al.* (2017) 'Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly', *Experimental Biology and Medicine*, 242(7), pp. 744–749. doi: 10.1177/1535370217693113.
- Mantovani, A. and Targher, G. (2017) 'Type 2 diabetes mellitus and risk of hepatocellular carcinoma : spotlight on nonalcoholic fatty liver disease', 5(13), pp. 1–12. doi: 10.21037/atm.2017.04.41.
- Margetts, J. *et al.* (2017) 'Neutrophils : driving progression and poor prognosis in hepatocellular carcinoma ?', *Nature Publishing Group*, 118(2), pp. 248–257. doi: 10.1038/bjc.2017.386.
- Mcglynn, K. A., Petrick, J. L. and London, W. T. (2022) 'Global Epidemiology of Hepatocellular Carcinoma An Emphasis on Demographic and Regional Variability', *Clinics in Liver Disease*, 19(2), pp. 223–238. doi: 10.1016/j.cld.2015.01.001.
- Mouchli, M. *et al.* (2020) 'Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article', *Annals of Hepatology*. doi: 10.1016/j.aohep.2020.08.067.
- Nault, J. (2014) 'Best Practice & Research Clinical Gastroenterology Pathogenesis of hepatocellular carcinoma according to aetiology', *Best Practice & Research Clinical Gastroenterology*, 28(5), pp. 937–947. doi: 10.1016/j.bpg.2014.08.006.
- Olivia, C. *et al.* (2020) 'Risk factors of mortality in the patients with hepatocellular carcinoma : A multicenter study in Indonesia', *Current Problems in Cancer*, 44(1), p. 100480. doi: 10.1016/j.currproblcancer.2019.05.003.
- Omata, M. *et al.* (2010) 'Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma', *Hepatology International*, 4(2), pp. 439–474. doi: 10.1007/s12072-010-9165-7.

- Palliyaguru, D. L. and Wu, F. (2013) 'Food Additives & Contaminants : Part A Global geographical overlap of aflatoxin and hepatitis C : controlling risk factors for liver cancer worldwide', 0049.
doi: 10.1080/19440049.2012.751630.
- PERKENI (2019) 'Pengelolaan dan Pengobatan Diabetes Melitus Tipe 2 Dewasa', *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, 1, p. 132.
- Petrick, J. L. *et al.* (2018) 'Tobacco , alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project', *British Journal of Cancer*, (January). doi: 10.1038/s41416-018-0007-z.
- van der Poll, T., Shankar-Hari, M. and Wiersinga, W. J. (2021) 'The immunology of sepsis', *Immunity*, 54(11), pp. 2450–2464.
doi: 10.1016/j.immuni.2021.10.012.
- Ponnappan, S. and Ponnappan, U. (2011) 'Aging and immune function: Molecular mechanisms to interventions', *Antioxidants and Redox Signaling*, 14(8), pp. 1551–1585. doi: 10.1089/ars.2010.3228.
- Qi, X. *et al.* (no date) 'Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies', 7(29).
- Rahayu, W. P. *et al.* (2020) 'Risk estimation of hepatocellular carcinoma due to exposure to aflatoxins in maize from yogyakarta, Indonesia', *Journal of Food Quality and Hazards Control*, 7(1), pp. 45–50.
doi: 10.18502/JFQHC.7.1.2451.
- Reig, M. *et al.* (2022) 'BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update', *Journal of Hepatology*, 76(3), pp. 681–693. doi: 10.1016/j.jhep.2021.11.018.
- Sachdeva, M., Chawla, Y. K. and Arora, S. K. (2015) 'Immunology of hepatocellular carcinoma', 7(17), pp. 2080–2090. doi: 10.4254/wjh.v7.i17.2080.

- Sansone, V. *et al.* (2021) ‘Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib’, *Clinical and Translational Gastroenterology*, 12(1), pp. 1–7. doi: 10.14309/ctg.0000000000000286.
- Singal, A. G. and El-serag, H. B. (2022) ‘Hepatocellular Carcinoma From Epidemiology to Prevention : Translating Knowledge into Practice’, *Clinical Gastroenterology and Hepatology*, 13(12), pp. 2140–2151. doi: 10.1016/j.cgh.2015.08.014.
- Singal, A. G., Lampertico, P. and Nahon, P. (2020) ‘Epidemiology and surveillance for hepatocellular carcinoma : New trends’, *Journal of Hepatology*, 72(2), pp. 250–261. doi: 10.1016/j.jhep.2019.08.025.
- Sipeki, N. *et al.* (2014) ‘Immune dysfunction in cirrhosis’, *World Journal of Gastroenterology*, 20(10), pp. 2564–2577. doi: 10.3748/wjg.v20.i10.2564.
- Sirivatanauksorn, Y. and Tovikkai, C. (2011) ‘Comparison of Staging Systems of Hepatocellular Carcinoma’, 2011. doi: 10.1155/2011/818217.
- Soyuoz, A. *et al.* (2018) ‘Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes’, *European Journal of Rheumatology*, 5(1), pp. 32–36. doi: 10.5152/eurjrheum.2017.17088.
- Stefaniuk, P., Szymczyk, A. and Podhorecka, M. (2020) ‘The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review’, pp. 2961–2977.
- Stockman, J. A. (2013) ‘Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1’, *Yearbook of Pediatrics*, 2013, pp. 312–313. doi: 10.1016/j.yped.2012.03.092.
- Su, F., Ioannou, G. N. and Ch, B. M. B. (2019) ‘Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy’, 13(1). doi: 10.1002/cld.781.

- Tan Yifei, Wei Shiyong, Zhang Wei, Yang Jian, Yang Jiayin, Yan Lunan (2019) ‘Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection : a meta-analysis and systematic review’, pp. 705–713.
- Toyoda, H. *et al.* (2005) ‘Comparison of the Usefulness of Three Staging Systems for Hepatocellular Carcinoma (CLIP , BCLC , and JIS) in Japan’, (12), pp. 1764–1772. doi: 10.1111/j.1572-0241.2005.41943.x.
- Utama, A. *et al.* (2010) ‘Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia’, (70), pp. 1152–1160. doi: 10.1111/j.1478-3231.2010.02280.x.
- Vandenbulcke, H. *et al.* (2016) ‘Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis : a prospective study’, *Journal of Hepatology*. doi: 10.1016/j.jhep.2016.04.031.
- Varbobitis, I. and Papatheodoridis, G. V (2016) ‘The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy’, pp. 319–326.
- Vogel, A. *et al.* (2018a) ‘Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, *Annals of Oncology*, 29(Supplement 4), pp. iv238–iv255. doi: 10.1093/annonc/mdy308.
- Vogel, A. *et al.* (2018b) ‘Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, *Annals of Oncology*, 29(Supplement 4), pp. iv238–iv255. doi: 10.1093/annonc/mdy308.
- Wade, A. J. *et al.* (2018) ‘Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial’, *Trials*, 19(1), pp. 1–9. doi: 10.1186/s13063-018-2768-3.
- Wang, B., Huang, Y. and Lin, T. (2020) ‘Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma’, pp. 1–7.

- Wang, H. *et al.* (2020) ‘Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications’, *Journal of Immunology Research*, 2020. doi: 10.1155/2020/4904217.
- Wang, H. *et al.* (2021) ‘The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib’, (September).
- Wang, T. (2021) ‘Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE’, pp. 2589–2600.
- Xiao, W. *et al.* (2014) ‘Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma : a meta-analysis’, *BMC Cancer*, 14(1), pp. 1–10. doi: 10.1186/1471-2407-14-117.
- Xu, L. *et al.* (2017) ‘Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients’, 8(21), pp. 34954–34960.
- Zhang, Q. *et al.* (2020) ‘Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies’, 26(26), pp. 3720–3736. doi: 10.3748/wjg.v26.i26.3720.
- Zhao, H. *et al.* (2011) ‘ARID2: A new tumor suppressor gene in hepatocellular carcinoma’, *Oncotarget*, 2(11), pp. 886–891. doi: 10.18632/oncotarget.355.
- Zhu, R. X. *et al.* (2016) ‘Epidemiology of hepatocellular carcinoma in the Asia-Pacific region’, *Gut and Liver*, 10(3), pp. 332–339. doi: 10.5009/gnl15257.
- Zucman-rossi, J. *et al.* (2015) ‘Genetic Landscape and Biomarkers of Hepatocellular Carcinoma’, *YGASt*, 149(5), pp. 1226-1239.e4. doi: 10.1053/j.gastro.2015.05.061.